The stock of Flex Pharma Inc (NASDAQ:FLKS) is a huge mover today! The stock decreased 24.73% or $2.77 on October 13, hitting $8.43. About 290,234 shares traded hands or 671.78% up from the average. Flex Pharma Inc (NASDAQ:FLKS) has risen 71.52% since March 10, 2016 and is uptrending. It has outperformed by 64.00% the S&P500.
The move comes after 9 months negative chart setup for the $146.13 million company. It was reported on Oct, 13 by Barchart.com. We have $7.59 PT which if reached, will make NASDAQ:FLKS worth $14.61 million less.
Analysts await Flex Pharma Inc (NASDAQ:FLKS) to report earnings on November, 2. They expect $-0.80 earnings per share, down 50.94% or $0.27 from last year’s $-0.53 per share. After $-0.71 actual earnings per share reported by Flex Pharma Inc for the previous quarter, Wall Street now forecasts 12.68% negative EPS growth.
According to Zacks Investment Research, “Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts.”
More notable recent Flex Pharma Inc (NASDAQ:FLKS) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on January 28, 2015, also Quotes.Wsj.com with their article: “News Flex Pharma Inc.FLKS” published on January 24, 2015, Bostonglobe.com published: “Boston’s Flex Pharma raises $86.4 million in IPO” on January 29, 2015. More interesting news about Flex Pharma Inc (NASDAQ:FLKS) were released by: Businesswire.com and their article: “Flex Pharma Announces FLX-787 as Clinical Drug Candidate” published on November 10, 2015 as well as Bostonglobe.com‘s news article titled: “Flex Pharma developing treatments for muscle cramps” with publication date: October 23, 2014.
FLKS Company Profile
Flex Pharma, Inc., incorporated on February 26, 2014, is a biotechnology firm that is developing treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Firm operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s product candidates are based on the mechanism of action described as Chemical Neuro Stimulation, which is the process by which a small molecule chemical signal, acting topically, is translated into a neuronal sensory signal that produces a beneficial effect. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing products using TRP activators.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.